BG106291A - Метод за инхибиране на натрупване от амилоиден протеин и за изобразяване на амилоидни отлагания, използвайки производни на изоиндолин - Google Patents

Метод за инхибиране на натрупване от амилоиден протеин и за изобразяване на амилоидни отлагания, използвайки производни на изоиндолин Download PDF

Info

Publication number
BG106291A
BG106291A BG106291A BG10629102A BG106291A BG 106291 A BG106291 A BG 106291A BG 106291 A BG106291 A BG 106291A BG 10629102 A BG10629102 A BG 10629102A BG 106291 A BG106291 A BG 106291A
Authority
BG
Bulgaria
Prior art keywords
phenyl
dihydro
isoindol
ylamino
benzoic acid
Prior art date
Application number
BG106291A
Other languages
Bulgarian (bg)
English (en)
Inventor
Corinne AUGELLI-SZAFRAN
Yingjie Lai
Annette SAKKAB
Lary WALKER
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG106291A publication Critical patent/BG106291A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BG106291A 1999-06-10 2002-01-09 Метод за инхибиране на натрупване от амилоиден протеин и за изобразяване на амилоидни отлагания, използвайки производни на изоиндолин BG106291A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13854399P 1999-06-10 1999-06-10
PCT/US2000/015073 WO2000076969A1 (en) 1999-06-10 2000-05-31 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Publications (1)

Publication Number Publication Date
BG106291A true BG106291A (bg) 2002-05-31

Family

ID=22482508

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106291A BG106291A (bg) 1999-06-10 2002-01-09 Метод за инхибиране на натрупване от амилоиден протеин и за изобразяване на амилоидни отлагания, използвайки производни на изоиндолин

Country Status (38)

Country Link
EP (1) EP1192131B1 (is)
JP (1) JP2003502313A (is)
KR (1) KR20020012266A (is)
CN (1) CN1156445C (is)
AP (1) AP1398A (is)
AT (1) ATE272623T1 (is)
AU (1) AU777747B2 (is)
BG (1) BG106291A (is)
BR (1) BR0011446A (is)
CA (1) CA2373394A1 (is)
CR (1) CR6530A (is)
CZ (1) CZ20014366A3 (is)
DE (1) DE60012742T2 (is)
DK (1) DK1192131T3 (is)
DZ (1) DZ3262A1 (is)
EA (1) EA004405B1 (is)
EE (1) EE200100666A (is)
ES (1) ES2223531T3 (is)
GE (1) GEP20043407B (is)
HK (1) HK1046283B (is)
HR (1) HRP20020027A2 (is)
HU (1) HUP0201586A2 (is)
IL (1) IL146455A0 (is)
IS (1) IS6162A (is)
MA (1) MA26807A1 (is)
MX (1) MXPA01011112A (is)
NO (1) NO20015992L (is)
NZ (1) NZ515619A (is)
OA (1) OA11958A (is)
PL (1) PL352294A1 (is)
PT (1) PT1192131E (is)
SI (1) SI1192131T1 (is)
SK (1) SK17622001A3 (is)
TR (1) TR200200257T2 (is)
UA (1) UA64842C2 (is)
WO (1) WO2000076969A1 (is)
YU (1) YU86801A (is)
ZA (1) ZA200109164B (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
SK17632001A3 (sk) * 1999-06-10 2003-03-04 Warner-Lambert Company Liečivo na liečbu Alzheimerovej choroby, inhibíciu agregácie amyloidového proteínu a spôsob na zobrazenie depozít amyloidu
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
CA2357450A1 (en) * 2000-09-29 2002-03-29 Warner-Lambert Company Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0031302D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
PE20040844A1 (es) * 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
GB2404855A (en) * 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
AR061623A1 (es) 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
KR101450356B1 (ko) * 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2687513B1 (en) * 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
EA019685B1 (ru) 2009-02-06 2014-05-30 Янссен Фармасьютикалз, Инк. Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
BRPI1011190A8 (pt) * 2009-05-07 2016-11-16 Janssen Pharmaceuticals Inc Derivados de indazol e aza-indazol substituídos como moduladores de gama secretase
ES2519565T3 (es) 2009-07-15 2014-11-07 Janssen Pharmaceuticals Inc. Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa
EP2523949B1 (en) 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Novel substituted triazole derivatives as gamma secretase modulators
CA2827969A1 (en) 2011-03-24 2012-09-27 Janssen Pharmaceuticals, Inc. Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
NZ702611A (en) 2012-05-16 2016-10-28 Cellzome Ltd Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
ES2612215T3 (es) 2013-01-17 2017-05-12 Janssen Pharmaceutica, N.V. Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
US10081629B2 (en) * 2014-04-14 2018-09-25 Jiangsu Hengrui Medicine Co., Ltd. Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof
SI3186241T1 (sl) * 2014-08-29 2021-03-31 Chdi Foundation, Inc. Sonde za slikanje Huntingtonovega proteina
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
CN110225753B (zh) * 2017-01-28 2022-12-09 金凯(辽宁)生命科技股份有限公司 用于制备5-苯氧基-1(3h)异苯并呋喃酮的方法
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CA3226162A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide

Also Published As

Publication number Publication date
CN1156445C (zh) 2004-07-07
IS6162A (is) 2001-11-15
YU86801A (sh) 2004-07-15
ES2223531T3 (es) 2005-03-01
NO20015992L (no) 2002-02-06
NZ515619A (en) 2003-05-30
BR0011446A (pt) 2002-03-19
SK17622001A3 (sk) 2003-06-03
HRP20020027A2 (en) 2005-02-28
DE60012742D1 (de) 2004-09-09
EA004405B1 (ru) 2004-04-29
DE60012742T2 (de) 2005-01-13
ZA200109164B (en) 2003-02-06
WO2000076969A1 (en) 2000-12-21
HK1046283B (zh) 2005-01-07
HK1046283A1 (en) 2003-01-03
NO20015992D0 (no) 2001-12-07
GEP20043407B (en) 2004-05-10
UA64842C2 (uk) 2004-03-15
JP2003502313A (ja) 2003-01-21
CZ20014366A3 (cs) 2002-11-13
ATE272623T1 (de) 2004-08-15
IL146455A0 (en) 2002-07-25
MA26807A1 (fr) 2004-12-20
AP1398A (en) 2005-04-21
MXPA01011112A (es) 2002-06-04
AP2002002389A0 (en) 2002-03-31
CA2373394A1 (en) 2000-12-21
EE200100666A (et) 2003-02-17
EP1192131B1 (en) 2004-08-04
PT1192131E (pt) 2004-11-30
SI1192131T1 (en) 2004-12-31
EP1192131A1 (en) 2002-04-03
CR6530A (es) 2004-03-24
CN1355790A (zh) 2002-06-26
DZ3262A1 (fr) 2000-12-12
TR200200257T2 (tr) 2002-06-21
OA11958A (en) 2006-04-13
EA200101133A1 (ru) 2002-06-27
HUP0201586A2 (en) 2002-08-28
DK1192131T3 (da) 2004-12-13
KR20020012266A (ko) 2002-02-15
AU5312000A (en) 2001-01-02
AU777747B2 (en) 2004-10-28
PL352294A1 (en) 2003-08-11

Similar Documents

Publication Publication Date Title
BG106291A (bg) Метод за инхибиране на натрупване от амилоиден протеин и за изобразяване на амилоидни отлагания, използвайки производни на изоиндолин
US6001331A (en) Method of imaging amyloid deposits
US6949575B2 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
WO2005016888A1 (ja) アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
JP2003502321A (ja) ローダニン誘導体ならびにアミロイドの阻害および画像化におけるその使用
US20040180943A1 (en) Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis
MXPA01010490A (es) Derivados rodanina para usarse en un metodo de inhibicion de la agregacion de proteinas amiloides y la formacion de imagenes de los depositos amiloides.
EP1193260B1 (en) Phenoxazine analogs for the treatment of amyloidosis
US20040197268A1 (en) Method of imaging amyloid deposits using substituted rhodanine derivatives